Synthesis, antimicrobial activity, attenuation of aminoglycoside resistance in MRSA, and ribosomal A-site binding of pyrene-neomycin conjugates

Sandra Story; Michael J. Skriba; Krishnagopal Maiti; Ranjan Nihar Ranjan; Natalya N. Degtyareva; Keith D. Green; Verjine Khodaverdian; Adegboyega K. Oyelere; Sylvie Garneau-Tsodikova; Dev P. Arya

doi:10.1016/j.ejmech.2018.11.022

Synthesis, antimicrobial activity, attenuation of aminoglycoside resistance in MRSA, and ribosomal A-site binding of pyrene-neomycin conjugates

Sandra Story, Michael J. Skriba, Krishnagopal Maiti, Ranjan Nihar Ranjan, Natalya N. Degtyareva, Keith D. Green, Verjine Khodaverdian, Adegboyega K. Oyelere, Sylvie Garneau-Tsodikova, Dev P. Arya

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

The development of new ligands that have comparable or enhanced therapeutic efficacy relative to current drugs is vital to the health of the global community in the short and long term. One strategy to accomplish this goal is to functionalize sites on current antimicrobials to enhance specificity and affinity while abating resistance mechanisms of infectious organisms. Herein, we report the synthesis of a series of pyrene-neomycin B (PYR-NEO) conjugates, their binding affinity to A-site RNA targets, resistance to aminoglycoside-modifying enzymes (AMEs), and antibacterial activity against a wide variety of bacterial strains of clinical relevance. PYR-NEO conjugation significantly alters the affinities of NEO for bacterial A-site targets. The conjugation of PYR to NEO significantly increased the resistance of NEO to AME modification. PYR-NEO conjugates exhibited broad-spectrum activity towards Gram-positive bacteria, including improved activity against NEO-resistant methicillin-resistant Staphylococcus aureus (MRSA) strains.

Original language	English
Pages (from-to)	381-393
Number of pages	13
Journal	European Journal of Medicinal Chemistry
Volume	163
DOIs	https://doi.org/10.1016/j.ejmech.2018.11.022
State	Published - Feb 1 2019

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Masson SAS

Funding

We thank the National Institute of Health for financial support (grants GM097917, AI111414 to D.P.A.) and (grant AI090048 to S.G.-T.). We thank the National Institute of Health for financial support (grants GM097917 , AI111414 to D.P.A.) and (grant AI090048 to S.G.-T.).

Funders	Funder number
National Institute of Health National Institute of Minority and Health Disparities Loan Repayment Program
National Institutes of Health (NIH)	AI090048, AI111414
National Institutes of Health (NIH)
National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical Sciences	R42GM097917
National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical Sciences

Keywords

Aminoglycoside
MRSA
Neomycin
RNA
Ribosome

ASJC Scopus subject areas

Pharmacology
Drug Discovery
Organic Chemistry

Access to Document

10.1016/j.ejmech.2018.11.022

Cite this

Story, S., Skriba, M. J., Maiti, K., Nihar Ranjan, R., Degtyareva, N. N., Green, K. D., Khodaverdian, V., Oyelere, A. K., Garneau-Tsodikova, S., & Arya, D. P. (2019). Synthesis, antimicrobial activity, attenuation of aminoglycoside resistance in MRSA, and ribosomal A-site binding of pyrene-neomycin conjugates. European Journal of Medicinal Chemistry, 163, 381-393. https://doi.org/10.1016/j.ejmech.2018.11.022

@article{140b90acd5c64b7784eadd44fb08b926,

title = "Synthesis, antimicrobial activity, attenuation of aminoglycoside resistance in MRSA, and ribosomal A-site binding of pyrene-neomycin conjugates",

abstract = "The development of new ligands that have comparable or enhanced therapeutic efficacy relative to current drugs is vital to the health of the global community in the short and long term. One strategy to accomplish this goal is to functionalize sites on current antimicrobials to enhance specificity and affinity while abating resistance mechanisms of infectious organisms. Herein, we report the synthesis of a series of pyrene-neomycin B (PYR-NEO) conjugates, their binding affinity to A-site RNA targets, resistance to aminoglycoside-modifying enzymes (AMEs), and antibacterial activity against a wide variety of bacterial strains of clinical relevance. PYR-NEO conjugation significantly alters the affinities of NEO for bacterial A-site targets. The conjugation of PYR to NEO significantly increased the resistance of NEO to AME modification. PYR-NEO conjugates exhibited broad-spectrum activity towards Gram-positive bacteria, including improved activity against NEO-resistant methicillin-resistant Staphylococcus aureus (MRSA) strains.",

keywords = "Aminoglycoside, MRSA, Neomycin, RNA, Ribosome",

author = "Sandra Story and Skriba, \{Michael J.\} and Krishnagopal Maiti and \{Nihar Ranjan\}, Ranjan and Degtyareva, \{Natalya N.\} and Green, \{Keith D.\} and Verjine Khodaverdian and Oyelere, \{Adegboyega K.\} and Sylvie Garneau-Tsodikova and Arya, \{Dev P.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Masson SAS",

year = "2019",

month = feb,

day = "1",

doi = "10.1016/j.ejmech.2018.11.022",

language = "English",

volume = "163",

pages = "381--393",

}

Story, S, Skriba, MJ, Maiti, K, Nihar Ranjan, R, Degtyareva, NN, Green, KD, Khodaverdian, V, Oyelere, AK, Garneau-Tsodikova, S & Arya, DP 2019, 'Synthesis, antimicrobial activity, attenuation of aminoglycoside resistance in MRSA, and ribosomal A-site binding of pyrene-neomycin conjugates', European Journal of Medicinal Chemistry, vol. 163, pp. 381-393. https://doi.org/10.1016/j.ejmech.2018.11.022

TY - JOUR

T1 - Synthesis, antimicrobial activity, attenuation of aminoglycoside resistance in MRSA, and ribosomal A-site binding of pyrene-neomycin conjugates

AU - Story, Sandra

AU - Skriba, Michael J.

AU - Maiti, Krishnagopal

AU - Nihar Ranjan, Ranjan

AU - Degtyareva, Natalya N.

AU - Green, Keith D.

AU - Khodaverdian, Verjine

AU - Oyelere, Adegboyega K.

AU - Garneau-Tsodikova, Sylvie

AU - Arya, Dev P.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The development of new ligands that have comparable or enhanced therapeutic efficacy relative to current drugs is vital to the health of the global community in the short and long term. One strategy to accomplish this goal is to functionalize sites on current antimicrobials to enhance specificity and affinity while abating resistance mechanisms of infectious organisms. Herein, we report the synthesis of a series of pyrene-neomycin B (PYR-NEO) conjugates, their binding affinity to A-site RNA targets, resistance to aminoglycoside-modifying enzymes (AMEs), and antibacterial activity against a wide variety of bacterial strains of clinical relevance. PYR-NEO conjugation significantly alters the affinities of NEO for bacterial A-site targets. The conjugation of PYR to NEO significantly increased the resistance of NEO to AME modification. PYR-NEO conjugates exhibited broad-spectrum activity towards Gram-positive bacteria, including improved activity against NEO-resistant methicillin-resistant Staphylococcus aureus (MRSA) strains.

AB - The development of new ligands that have comparable or enhanced therapeutic efficacy relative to current drugs is vital to the health of the global community in the short and long term. One strategy to accomplish this goal is to functionalize sites on current antimicrobials to enhance specificity and affinity while abating resistance mechanisms of infectious organisms. Herein, we report the synthesis of a series of pyrene-neomycin B (PYR-NEO) conjugates, their binding affinity to A-site RNA targets, resistance to aminoglycoside-modifying enzymes (AMEs), and antibacterial activity against a wide variety of bacterial strains of clinical relevance. PYR-NEO conjugation significantly alters the affinities of NEO for bacterial A-site targets. The conjugation of PYR to NEO significantly increased the resistance of NEO to AME modification. PYR-NEO conjugates exhibited broad-spectrum activity towards Gram-positive bacteria, including improved activity against NEO-resistant methicillin-resistant Staphylococcus aureus (MRSA) strains.

KW - Aminoglycoside

KW - MRSA

KW - Neomycin

KW - RNA

KW - Ribosome

UR - http://www.scopus.com/inward/record.url?scp=85057585740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057585740&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.11.022

DO - 10.1016/j.ejmech.2018.11.022

M3 - Article

C2 - 30530174

AN - SCOPUS:85057585740

SN - 0223-5234

VL - 163

SP - 381

EP - 393

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

ER -

Synthesis, antimicrobial activity, attenuation of aminoglycoside resistance in MRSA, and ribosomal A-site binding of pyrene-neomycin conjugates

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this